Laron Z, Anin S, Klipper-Aurbach Y, Klinger B
Institute of Paediatric and Adolescent Endocrinology, Children's Medical Centre, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel.
Lancet. 1992 May 23;339(8804):1258-61. doi: 10.1016/0140-6736(92)91594-x.
Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.
拉伦型侏儒症患者在临床上与单纯生长激素（GH）缺乏症患者无法区分，但循环中的GH浓度很高，同时无法产生内源性胰岛素样生长因子I（IGF-I）。对5名年龄在3.3至14.5岁的拉伦型侏儒症儿童，每天皮下注射一次生物合成IGF-I，持续3至10个月。结果发现，患者肢体的线性生长迅速受到刺激，头围显著增加，体重增加，皮下脂肪减少。对拉伦型侏儒症患者使用IGF-I似乎对生长有有益影响，类似于在GH缺乏症儿童中长期使用GH所观察到的效果。
